Min­neso­ta judge nar­rows charges in class ac­tion suit against My­lan, phar­ma­cy ben­e­fit man­agers over EpiPen price hikes

Sec­ond time’s the charm for Vi­a­tris and a suite of phar­ma­cy ben­e­fit man­agers in a pro­posed class-ac­tion law­suit al­leg­ing col­lu­sion over price hikes for the com­pa­ny’s EpiPen.

Af­ter try­ing — and suc­ceed­ing, in part — to get claims against them dis­missed back in 2021, the de­fen­dants cel­e­brat­ed a win on Tues­day when a Min­neso­ta fed­er­al judge dis­missed a large chunk of the claims due to a lack of ev­i­dence.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.